However, 18F-PSMA analogs seemed to be more favorable due to their longer half-life and a higher physical spatial resolution, and [18F]PSMA-1007, as a second-generation 18F-labeled PSMA tracer, demonstrated high labeling yields, better tumor uptake, and hepatobiliary excretion, making it an ideal PSMA-target tracer for diagnostic imaging in patients with BCR. The gene discussed is FOLH1; the disease is neoplasm.